dsdsa

product

2020 China New Design Lorcaserin Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

We offer great strength in quality and development,merchandising,sales and marketing and operation for 108736-35-2, 1187594-09-7, 33069-62-4, At our firm with quality first as our motto, we manufacture products that are entirely made in Japan, from materials procurement to processing. This enables them to be used with confident peace of mind.
2020 China New Design Lorcaserin Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai Detail:

Product name Tofacitinib Citrate
Synonyms (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate; CP 690500-10; CP 690550-10; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate
CAS No. 540737-29-9
Appearance Off white to white powder
Molecular Formula C16H20N6O.C6H8O7
Molecular Weight 504.50
Application Pharmaceutical grade or research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Tofacitinib Citrate (CAS #540737-29-9)

ITEMS

STANDARDS

RESULTS

Appearance

Off white to white powder

Off white powder

Identification

HPLC; IR; HNMR

Complies

Solubility

Soluble in DMSO at 100mg/ml, very poorly soluble in ethanol, sparingly soluble in water etc.

Complies

Loss on Drying

≤0.5%

0.12%

Residue on ignition

≤0.1%

0.05%

Heavy metals

≤10ppm

Complies

Related Substances

Diastereomer (RS+SR) ≤0.1%

Single Impurity ≤0.15%

Total impurities ≤1.0%

0.05%

0.14%

0.18%

Enantiomorphism Isomers

≤0.2%

Complies

Residual Solvents

Ethanol ≤5000ppm

Methanol ≤3000ppm

Toluene ≤890ppm

Complies

Citrate Content

36.2%~40%

37.8%

Purity

≥99.0%

99.38%

Assay

60.68%~63.16% of Tofacitinib INN

98%~102% of Tofacitinib Citrate INN

62.04%

 

99.12%

Conclusion:Complies

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

2020 China New Design Lorcaserin Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

2020 China New Design Lorcaserin Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

2020 China New Design Lorcaserin Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures


Related Product Guide:

Our goal is to satisfy our customers by offering golden service, good price and high quality for 2020 China New Design Lorcaserin Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai , The product will supply to all over the world, such as: Pakistan, moldova, Vietnam, Our items have national accreditation requirements for qualified, high quality products, affordable value, was welcomed by people today all over the world. Our goods will continue to enhance within the order and look forward to cooperation with you, Should any of these products be of interest to you, please letus know. We are going to be content to offer you a quotation up on receipt of your detailed needs.
  • In China, we have many partners, this company is the most satisfying to us, reliable quality and good credit, it is worth appreciation.
    5 Stars By Danny from Georgia - 2017.04.08 14:55
    We feel easy to cooperate with this company, the supplier is very responsible, thanks.There will be more in-depth cooperation.
    5 Stars By Elaine from Guatemala - 2017.04.28 15:45
    Write your message here and send it to us